Drug Trial Radar · NCT06310590
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 8, 2023
Primary completion
Jun 10, 2025
Study completion Jun 10, 2025
Sponsor
- Lead sponsor
- Chengdu New Radiomedicine Technology Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
Conditions
- Unresectable Hepatocellular Carcinoma
Interventions
NRT6003 InjectionDrug
Selective internal radiation therapy (SIRT) with TareSphere
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events/ Severe adverse eventsTime frame: Up to 12 months
- Localized Objective response rates (ORR)Time frame: Up to 6 months (initial tumor assessment after administration)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, China
Anhui Provincial Hospital
Hefei, Anhui, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.